Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.
Paczkowska J, Tang M, Wright KT, Song L, Luu K, Shanmugam V, Welsh EL, Weirather JL, Besson N, Olszewski H, Porter BA, Pfaff KL, Redd RA, Cader FZ, Mandato E, Ouyang J, Calabretta E, Bai G, Lawton LN, Armand P, Rodig SJ, Liu XS, Shipp MA. Paczkowska J, et al. Among authors: welsh el. Nat Commun. 2024 Dec 30;15(1):10740. doi: 10.1038/s41467-024-54512-7. Nat Commun. 2024. PMID: 39737927 Free PMC article.
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. Sudalagunta PR, et al. Among authors: welsh ea. Cancer Res. 2025 Jan 15;85(2):378-398. doi: 10.1158/0008-5472.CAN-24-0886. Cancer Res. 2025. PMID: 39476082 Free PMC article.
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, Besson NR, Jones SM, Welsh EL, Pfaff KL, Barletta JA, Park J, Reardon B, Doherty GM, Alexander EK, Rodig SJ, Barbie DA, O'Neill A, Van Allen E, Haddad RI, Lorch JH. Sehgal K, et al. Among authors: welsh el. JAMA Oncol. 2024 Dec 1;10(12):1663-1671. doi: 10.1001/jamaoncol.2024.4019. JAMA Oncol. 2024. PMID: 39446365 Clinical Trial.
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM. Ricciuti B, et al. Among authors: welsh el. JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39399157 Free PMC article.
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.
Huffman BM, Rahma OE, Tyan K, Li YY, Giobbie-Hurder A, Schlechter BL, Bockorny B, Manos MP, Cherniack AD, Baginska J, Mariño-Enríquez A, Kao KZ, Maloney AK, Ferro A, Kelland S, Ng K, Singh H, Welsh EL, Pfaff KL, Giannakis M, Rodig SJ, Hodi FS, Cleary JM. Huffman BM, et al. Among authors: welsh el. Cancer Immunol Res. 2025 Jan 9;13(1):9-22. doi: 10.1158/2326-6066.CIR-23-1027. Cancer Immunol Res. 2025. PMID: 39348472 Clinical Trial.
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling.
Hu Q, Remsing Rix LL, Desai B, Miroshnychenko D, Li X, Welsh EA, Fang B, Wright GM, Chaudhary N, Kroeger JL, Doebele RC, Koomen JM, Haura EB, Marusyk A, Rix U. Hu Q, et al. Among authors: welsh ea. bioRxiv [Preprint]. 2024 Aug 28:2024.08.27.609975. doi: 10.1101/2024.08.27.609975. bioRxiv. 2024. PMID: 39253447 Free PMC article. Preprint.
IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America.
de Sanctis Pecora C, Trindade de Almeida A, Figueredo V, Hirano C, Bugallo A, Cortés C, Welsh EC, Spada J, Heredia N, de La Fuente V, Muniz M. de Sanctis Pecora C, et al. Among authors: welsh ec. Dermatol Surg. 2024 Sep 1;50(9S):S24-S34. doi: 10.1097/DSS.0000000000004343. Epub 2024 Jul 24. Dermatol Surg. 2024. PMID: 39196830 Review.
Stability of Nano-Emulsified Cannabidiol in Acidic Foods and Beverages.
Mullen LD, Hart ED, Vikingsson S, Winecker RE, Hayes E, Flegel R, Davis LD, Welsh ER, ElSohly M, Gul W, Murphy T, Shahzadi I, ElSohly K, Cone EJ. Mullen LD, et al. Among authors: welsh er. Cannabis Cannabinoid Res. 2024 Jun 18. doi: 10.1089/can.2024.0064. Online ahead of print. Cannabis Cannabinoid Res. 2024. PMID: 38888614
261 results